EverPoint Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

EverPoint Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5.97M	Buy	+417,849	New	+$6.35M	0.11%	220

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EverPoint Asset Management's CRVS Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q4 2016: 417,849 shares worth $5.97M. The stake represents 0.11% of the portfolio and ranks #220 among its holdings.

53 funds tracked by Wall St. Rank hold CRVS as of Q4 2016.

EverPoint Asset Management held 417,849 shares of Corvus Pharmaceuticals worth $5.97M as of Q4 2016.
Corvus Pharmaceuticals was a new EverPoint Asset Management position in Q4 2016.
Corvus Pharmaceuticals made up 0.11% of EverPoint Asset Management's portfolio in Q4 2016, its #220 holding.
53 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.